7:30 am – 8:30 am REGISTRATION & CONTINENTAL BREAKFAST
8:30 am–9:30 am Setting the Stage: Why Are We Here? Outline challenges ahead and frame the learning experience for MedEd Forum
MedEd Planning: Setting Global Educational Goals and Strategies An overview of the process of setting strategic goals and priorities
Maureen Doyle-Scharff, MBA, FACME, Director, Medical Education, U.S. External Medical Affairs, Pfizer Inc
Pamela L. Mason, BS, FACME, CCMEP, Director of Medical Education Grants Office, AstraZeneca
Mike Saxton, MEd, FACME, Senior Director, Team Leader, Medical Education Group, U.S. External Medical Affairs, Pfizer Inc
Hilary Schmidt, Ph.D., Associate Vice President, Medical Education, Medical Communications, sanofi-aventis
9:30 am – 5:00 am MANAGING APPROPRIATE BIAS
KEYNOTE ADDRESS
9:30 am–10:15 am Review of Literature on the Relationship between Commercial Support and Bias in CME Concerns specifically about the potential for bias in CME have been raised by several influential bodies because there has been widespread belief that the safeguards the profession has erected to assure that CME is free of commercial bias have not been successful. This address discusses the research and reviews the bias in CME. Hear about:
Studies of the relationship between commercial support and bias inaccredited CME
Studies on the impact of commercially supported CME on prescribing practice
Studies on physician opinions about bias in commercially supported CME
Studies on how to measure bias in commercially supported CME
Ronald M. Cervero, Ph.D., Professor and Head, Department of Lifelong Education, Administration and Policy, The University of Georgia
10:15 NETWORKING AND REFRESHMENT BREAK
PANEL DISCUSSION
10:45 am – 12:00 pm Stakeholder Perspectives on Bias in CME Commercial support of CME continues to be criticized from academia, media and regulators directed toward perceived bias. This panel provides a variety of perspectives on the controversies surrounding industry influences.
Types of bias
Research on the bias in CME
* social science findings
Moderator: Jann Balmer, RN, Ph.D., Director of CME, University of Virginia School of Medicine Panel: Ronald M. Cervero Ph.D., Professor and Head, Department of Lifelong Education, Administration and Policy, The University of Georgia Susan Chimoneas, Co-Director Research, Columbia University Medical Center Mindi McKenna, Ph.D., MBA, Director, Division of Continuing Medical Education, American Academy of Family Physicians
12:00 NETWORKING LUNCHEON
1:00 pm – 2:00 pm Alliance for CME Level III Accreditation Webinar
2:00 NETWORKING AND REFRESHMENT BREAK
2:30 pm – 4:30 pm Birds of a Feather — Practical Solutions to ManagingBias Breakout These breakouts are solution- based on how to manage bias and boundaries. Hear from your peers on what has worked, what has not and particularly about creativity in achieving quality while ensuring compliance. The working groups include participants with a facilitator to engage in an open and honest discussion of the practical issuesbehind these programs.
Commercial Supporters
Policy/Procedures
Screening providers
Communication/Tools to develop appropriate bias
Managing bias and boundaries
Pamela L. Mason, BS, FACME, CCMEP, Director of Medical Education Grants Office, AstraZeneca
CME Providers
Policy/Procedures
Communication
Needs assessment
Mark H. Schaffer, EdM, FACME, Vice President, CME Compliance, Professional Postgraduate Services
4:30 pm – 5:00 pm Summaries of Breakouts/Key Findings and Cross Discussion
Pamela L. Mason, BS, FACME, CCMEP, Director of Medical Education Grants Office, AstraZeneca
Mark H. Schaffer, EdM, FACME, Vice President, CME Compliance, Professional Postgraduate Services 5:00 END OF DAY ONE
8:00 am–8:45 am Impact of Legislations on CME In this session, review the political issues surrounding CME and the impacts they have on funding certified CME.
Regulatory impacts on grants
Update on accreditation
Strategies to ensure compliance
John Kamp, JD, Ph.D., Executive Director, Coalition for Healthcare Communication; Of Counsel, Wiley Rein
8:45 am – 9:30 am The ACME Competencies for CME Professionals, the ACCME Updated Criteria and Grant Review — Where’s the Intersection and How Can It Improve the Quality of Grants? This session provides an update on the ACME Core Competencies for CME professionals and illustrates how a critical subset of these competencies is fundamental to achieving the goals of the ACCME Criteria and guiding high quality grant review. Interactive activities enable participants to become familiar with the competencies, to analyze their relationship to the ACCME Update Criteria and to explore how achieving these competencies are coreto development and execution of high quality, rigorous grant review criteria.
Hilary Schmidt, Ph.D., Associate Vice President, Medical Education, Medical Communications, sanofi-aventis
Sterling North, Director of CME, University of Maryland, School of Medicine
9:30 NETWORKING & REFRESHMENT BREAK
10:00 am – 10:45 am Update on PhRMA Code Hear from PhRMA regarding the code revisions. Changes include:
Financial support for CME
Separation of grants for sales and marketing
Clear distinction of CME from speaker bureaus
Ann Leopold Kaplan, Assistant General Counsel, PhRMA
PANEL DISCUSSION
10:45 am – 11:45 am Panel Discussion on Enforcement Oversight on Transparency This panel discusses guidelines and initiatives currently in place as well as what is still pending in terms of initiatives regarding transparency. Attendees also have the opportunity to pose questions to this elite panel of experts.
Varying perspectives on going transparency
Challenges faced
Moderator: John Kamp, JD, Ph.D., Executive Director, Coalition for Healthcare Communication; Of Counsel, Wiley Rein
Panelists: Robert Restuccia, Executive Director, Prescription Project
Christopher J. Armstrong, Esq. Investigative Counsel, Committee on Finance, The Honorable Chuck Grassley, Ranking Member, United States Senate
Ann Leopold Kaplan, Assistant General Counsel, PhRMA Michael Loucks, First Assistant, U.S. Attorney
11:45 NETWORKING LUNCHEON 1:00 pm – 3:00 pm Birds of a Feather — Transparency — What Does it Mean to Implement? Transparency is a term/policy applied by U.S. Senators and others as part of the “Sunshine Act” legislation working its way through congress. Some pharmaceutical companies have chosen to proactively post a list of their educational grants on-line as evidence of transparency. Other companies are either in the process or at least giving it serious consideration. These breakouts are solution-based on how to interpret policies surrounding grant transparency and how it can apply to your company. Hear from your peers on their initiatives/challenges while creating “transparency”, as well as from those who have opted to wait for further interpretation. Come away with strategies/ideas for implementing a “grant transparency” program while remaining in compliance. The working groups include participants with a facilitator to engage in an open and honest discussion of the practical issues behind these programs.
Commercial Supporters
Hear unique perspectives from 3 companies at different stages of interpreting and implementing grant transparency.
Hear how some of these initiatives/guidelines are being communicated internally
Understand implications
Trials and tribulations
Kristin Rand, JD, Independent Medical Education (IMED), Genentech
Beth Brillinger, Senior Medical Education Manager, AstraZeneca
Jacqueline Mayhew, Education Director, Pfizer Inc Brian S. McGowan, PhD, CCMEP, Senior Director, Independent Medical Education, Wyeth Pharmaceuticals
CME Providers In the CME community, the term transparency has been identified as a commercial supporter issue, something Pharma has to come to terms with. In reality, the provider side of the CME community needs to understand and embrace the transparency template for Pharma funded education to survive.
ACCME’s “new paradigm” and transparency
Designing transparent proposals
Working with government healthcare data
Robert L. Meinzer, Director National CME, New Jersey Academy of Family Physicians
3:00 NETWORKING & REFRESHMENT BREAK
3:30 pm – 4:00 pm Summaries of Breakouts/Key Findings and Cross Discussion Kristin Rand, JD, Independent Medical Education (IMED), Genentech
Beth Brillinger, Senior Medical Education Manager, AstraZeneca
Jacqueline Mayhew, Education Director, Pfizer Inc
Brian S. McGowan, PhD, CCMEP, Senior Director, Independent Medical Education, Wyeth Pharmaceuticals
Robert L. Meinzer, Director National CME, New Jersey Academy of Family Physicians
PANEL DISCUSSION
4:00 pm – 5:00 pm Reactions from Varying Companies on Current Guidelines This panel analyzes the current regulatory climate and issues surrounding policies raised throughout the day. Hear key points of concern and how to respond to the trends impacting CME initiatives.
Interpretations of PhRMA code
What companies can proactively do now to handle future challenges
Discuss strategies companies are taking to ensure compliance
Moderator: Maureen Doyle-Scharff, MBA, FACME, Director, Medical Education, U.S. External MedicalAffairs, Pfizer Inc
Panelists: Pamela L. Mason BS, FACME, CCMEP, Director of Medical Education Grants Office,AstraZeneca
Christine Beebe, Associate Director, Medical Communications,Takeda Tiffany D. Cummings, MBA Business Manager, Professional Education, Shire
Walter Wolneyiec
5:00 END OF DAY TWO
5:00 NETWORKING WINE & CHEESE RECEPTION
FRIDAY, December 5, 2008
7:30 am–8:00 am CONTINENTAL BREAKFAST
8:00 am–1:00 pm CME PRACTICUM
8:00 am – 9:00 am ACCME Implementation — Challenges and Opportunities with Respect to Commercial Support Issues
If there is such a thing as acceptable provider-supporter communication, what are the limits and boundaries of the interaction?
If there is such a thing as ACCME “best practices” for commercial supporters, what would they look like?
What will the future of funding CME be in 2009 and beyond?
George C. Mejicano, M.D., MS, Associate Dean for Continuing Professional Development, University of Wisconsin School of Medicine and Public Health
9:00 am – 10:30 am Grant Review — Hot Topics for Commercial Supporters
Redefining boundaries for communication
* capabilities presentations * education provider inquiries on interest * questions about a proposal * logistics questions once approved * education provider inquiries on funding decisions
Quality of grant proposals
Reconciliation metrics and outcomes
Valesta Tejan-Kamara, Senior Medical Education Manager, AstraZeneca
11:00 am – 12:30 pm A Call to Action – Innovative Steps Industry Can Take This interactive session discusses the topics uncovered throughout the forum and allows for Q&A. Benefit from a very interactive panel that synthesizes the two and half days and provides the audience with key take-aways and action items to implement back in the office.
Connecting the dots – Major themes/issues that arose throughout the forum
What can industry do to move forward?
* coming up with solutions versus problems
Identifying deficiencies
Improving standards of quality
Patrick Clinton, Editor-in-Chief, Pharmaceutical Executive
Mike Saxton, MEd, FACME, Senior Director, Team Leader, Medical Education Group, U.S. External Medical Affairs,Pfizer Inc
